v3.25.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenue:    
Total revenue $ 1,637,185 $ 1,576,286
Operating expenses    
Cost of revenue 1,044,929 850,234
Selling, general and administrative expenses 2,554,474 1,440,586
Research and development expenses 265,663 4,880
Loss on disposal of fixed assets 561,663
Impairment loss 14,645,069
Depreciation and amortization 234,462 226,960
Total operating expenses 18,744,597 3,084,323
Loss from operations (17,107,412) (1,508,037)
Other income (expense):    
Gain (loss) from equity method joint ventures 15,096 104
Gain on lease termination 94,551
Interest expense (311,270) (181,295)
Total other income (expense) (296,174) (86,640)
Net loss before income taxes (17,403,586) (1,594,677)
Income taxes 1,836
Net loss $ (17,403,586) $ (1,596,513)
Net loss per common share:    
Basic $ (12.53) $ (7.55)
Diluted $ (12.53) $ (7.55)
Weighted average number of common shares outstanding:    
Basic 1,389,141 211,329
Diluted 1,389,141 211,329
Clinic Revenue [Member]    
Revenue:    
Total revenue $ 1,621,553 $ 1,537,199
Product [Member]    
Revenue:    
Total revenue $ 15,632 $ 39,087